Delving into the Latest Updates on Guaifenesin with Synapse

Overview

Basic Info

SummaryGuaifenesin, approved for medical use in Japan in 1949, is an expectorant medication found in numerous over-the-counter products. Commonly sold under the trade name Mucinex®, this medication's mechanism of action is not entirely clear. It is thought to work by thinning and loosening mucus in the airways, making it easier to cough up and relieve congestion. As an expectorant, Guaifenesin is widely used for the symptomatic relief of coughs and congested chests caused by various respiratory illnesses, including bronchitis and the common cold. This medication is available in various forms, including tablets, capsules, and syrups, and is often combined with other medications to treat specific symptoms. Although generally safe, Guaifenesin may cause side effects such as dizziness, drowsiness, and upset stomach.

Drug Type

Small molecule drug

Synonyms

Glyceryl guaiacolate, Guaifenesin (JP17/USP/INN), Guaifenesine

+ [11]

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory Diseases

Active Indication

CoughSputum excretion difficultyRespiratory Diseases

Inactive Indication

Acute lower respiratory tract infectionAcute respiratory infectionsAcute upper respiratory infection+ [3]

Originator Organization

Kyoto Pharmaceutical Industries Ltd.

Active Organization

Kyoto Pharmaceutical Industries Ltd.

Reckitt Benckiser Group Plc

Reckitt Benckiser LLC

+ [1]

Inactive Organization

Reckitt Benckiser, Inc.

Hefei Cosource Pharmaceuticals, Inc.Anhui Pharmaceutical Technology Industrial Company

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (20 Mar 1949),

CoughSputum excretion difficulty

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H14O4

InChIKeyHSRJKNPTNIJEKV-UHFFFAOYSA-N

CAS Registry93-14-1

An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioequivalence Study Comparing Guaifenesin and Dextromethorphan Hydrobromide Extended Release Tablets 1200 mg by 60 mg Manufactured By Marksans Pharma Ltd Plot No L 82 L 83 Verna Industrial Estate Verna Goa 403722 With Mucinex DM Dextromethorphan HBr 60 mg and Guaifenesin 1200 mg Extended Release Tablets Distributed By RB Health US Parsippany NJ 07054 0224 in Healthy Adult Human Subjects Under Fed Conditions - NIL

Start Date10 Mar 2026

Sponsor / Collaborator

Marksans Pharma Ltd.

NCT06716645

/ CompletedPhase 4

A Real-World Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.

Start Date04 Dec 2024

Sponsor / Collaborator

Haleon Plc

CTR20232759

/ CompletedNot Applicable

愈创木酚甘油醚双层缓释片人体生物等效性研究

[Translation] Study on the bioequivalence of guaifenesin bilayer sustained-release tablets in healthy volunteers

采用单中心、随机、开放、双周期交叉、单次口服试验设计比较空腹和餐后给药条件下，北京柏雅联合药物研究所有限公司提供的愈创木酚甘油醚双层缓释片（600 mg）与RB HEALTH US LLC生产的愈创木酚甘油醚双层缓释片（600 mg，商品名：Mucinex®）在中国健康人群吸收程度和吸收速度的差异，并评价北京柏雅联合药物研究所有限公司提供的愈创木酚甘油醚双层缓释片的安全性。

[Translation]

A single-center, randomized, open, two-period crossover, single oral trial design was used to compare the differences in absorption extent and rate of guaifenesin bilayer sustained-release tablets (600 mg) provided by Beijing Boya United Pharmaceutical Research Institute Co., Ltd. and guaifenesin bilayer sustained-release tablets (600 mg, trade name: Mucinex®) produced by RB HEALTH US LLC in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of guaifenesin bilayer sustained-release tablets provided by Beijing Boya United Pharmaceutical Research Institute Co., Ltd.

Start Date04 Oct 2023

Sponsor / Collaborator

Beijing Baiya United Medicine Research Institute Co.,Ltd.

100 Clinical Results associated with Guaifenesin

Login to view more data

100 Translational Medicine associated with Guaifenesin

Login to view more data

100 Patents (Medical) associated with Guaifenesin

Login to view more data

914

Literatures (Medical) associated with Guaifenesin

01 Nov 2026·JOURNAL OF EQUINE VETERINARY SCIENCE

Comparison of xylazine–ketamine–guaifenesin and xylazine–tiletamine–zolazepam protocols for constant rate infusion anesthesia in horses undergoing field castration

Article

Author: Sangbunjong, Athicha ; Limrodpai, Jirakarn ; Chantong, Boonrat ; Vinijkumthorn, Ruethaiwan ; Karkkaew, Prem ; Maneephan, Photchanun ; Thepparat, Krittima ; Suwanekkasit, Benjawan

BACKGROUND:

The common use of "triple drip" (xylazine, ketamine, and guaifenesin; XKG) is a popular protocol for constant rate infusion (CRI) in equine practice. However, due to restrictions on ketamine and guaifenesin in many countries, tiletamine-zolazepam (TZ) could serve as an alternative. To date, there have been limited studies evaluating the use of xylazine in combination with TZ (XTZ) administered via CRI to maintain surgical anesthesia in equine field practice.

AIMS/OBJECTIVES:

To compare the effectiveness and safety of XTZ infusion with the classical XKG protocol for field anesthesia.

METHODS:

Twelve healthy stallions were randomly allocated to two groups (XKG and XTZ) for castration. All horses were premedicated with xylazine at 1 mg/kg intravenously (IV). The XKG group received ketamine at 2 mg/kg IV for induction, followed by maintenance with xylazine 1.375 mg/kg/h, ketamine 2.75 mg/kg/h and guaifenesin 68.75 mg/kg/h The XTZ group was induced with TZ at 1 mg/kg IV and maintained with xylazine 0.75 mg/kg/h and TZ 1.5 mg/kg/h RESULTS: No clinically significant differences of anesthetic effects and cardiorespiratory parameters were observed between the XTZ and XKG formulation.

CONCLUSIONS:

The preparation of the CRI XTZ might be effectively alternated the triple drip for maintaining anesthesia in equine field practice.

03 Jun 2026·CLINICAL TOXICOLOGY

Intentional pediatric nonprescription cold/cough and analgesic/antipyretic exposure trends amid the COVID-19 pandemic

Article

Author: Chang, Dorothy ; Karami, Sara ; Pinnow, Ellen ; Asonye, Ajoa ; McCulley, Lynda ; Ventura, Christian Angelo I. ; Zhou, Esther H. ; Dal Pan, Gerald J. ; Ibrahim, Ibrahim ; Meyer, Tamra

INTRODUCTION:

The objective of this study is to examine US Poison Center intentional pediatric nonprescription analgesics/antipyretic and cold/cough exposure trends involving abuse/misuse and suspected suicide amid the COVID-19 pandemic.

METHODS:

Using descriptive and interrupted time-series analyses, we assessed monthly pediatric (6-17 years) exposure case rates involving nonprescription analgesic/antipyretic drugs containing paracetamol (acetaminophen), ibuprofen, acetylsalicylic acid, and naproxen, and cold/cough drugs containing dextromethorphan, guaifenesin, pseudoephedrine, and phenylephrine, before (1/1/2015-2/29/2020) and during (4/1/2020-4/30/2023) the COVID-19 pandemic. Statins served as a control.

RESULTS:

Nearly half of pediatric intentional cough/cold (40-56%) and analgesic/antipyretic (51-62%) cases involved a single substance, unlike the control (22%). Most cases entailed intentional-suspected suicide exposures (cold/cough 55-78%; analgesic/antipyretic 89-92%; control 96%) followed by intentional-abuse/misuse (cold/cough 17-40%; analgesic/antipyretic 6-8%; control 3%). Cases commonly involved adolescents, 13-17 years (cold/cough 88-93%; analgesic/antipyretic 90-92%; control 88%) and females (cold/cough 56-71%; analgesic/antipyretic 84-85%; control 82%). Paracetamol intentional-abuse/misuse and dextromethorphan suspected suicide case rates declined immediately following the pandemic's onset (March 2020), among adolescents. Case rates for guaifenesin, paracetamol, and ibuprofen intentional-suspected suicides exceeded pre-pandemic levels and exhibited statistically significant increased trend changes for adolescents (0.016, 0.246, and 0.116 cases per million population per month, respectively); and for guaifenesin for female (0.03 cases per million population). Male and female intentional-abuse/misuse case rates trends for some study drugs also increased; primarily for adolescents.

CONCLUSION:

Some analgesic/antipyretic and cold/cough intentional-suspected suicide case rates notably increased during the pandemic for adolescents, particularly females. This surge aligns with periods of increased psychological stress, suicidal ideation/attempts, and certain nonprescription drug exposures potentially attributed to the COVID-19 pandemic.

12 May 2026·JOURNAL OF ZOO AND WILDLIFE MEDICINE

USE OF GUAIFENESIN-KETAMINE-XYLAZINE INFUSION FOR MAINTENANCE OF ANESTHESIA IN CAPTIVE PREZEWALSKI HORSES (EQUUS FERUS PRZEWALSKI ): A CASE SERIES

Article

Author: Johnson, James G ; Hausmann, Jennifer ; Hinkle, Stephanie ; Wiedner, Ellen

This case series documents the use of triple drip, a combination of IV guaifenesin, ketamine, and xylazine (GKX) to extend the length of anesthesia in zoo-owned Przewalski horses (Equus ferus przewalskii). In three separate procedures involving two different animals, GKX was used to prolong and deepen the plane of anesthesia for 90 to 120 min beyond an initial induction dart containing ketamine, butorphanol, azaperone, and medetomidine. The depth of anesthesia was sufficient to permit surgical excision of SC abscesses and other procedures. Throughout the anesthetic events, the horses breathed spontaneously and maintained normal cardiorespiratory parameters, demonstrated no response to noxious stimuli, and had excellent muscle relaxation. Recoveries were smooth in all cases. Development of anesthetic protocols without ultrapotent opioids has become a priority in zoological medicine due to decreased drug availability as well as safety considerations. This is the first report of an entirely ultrapotent narcotic-free anesthetic protocol for intermediate to extended length procedures in Przewalski horses.

27

News (Medical) associated with Guaifenesin

16 Sep 2026

·www.prnewswire.com

RECKITT INVESTS UP TO $600 MILLION TO ACCELERATE U.S.-BASED INNOVATION, EXPAND ACCESS TO HEALTHCARE PRODUCTS, AND STRENGTHEN SUPPLY RESILIENCE

Aims to unite commercial and R&D in North American Campus Establishes science and innovation center to become global germ protection hub Expands initial investment for its largest OTC manufacturing facility by 50% NUTLEY, N.J., Sept. 16, 2026 /PRNewswire/ -- Reckitt today announced up to a $600 million, multi-year transformation of its U.S. operations across two sites to accelerate the long-term growth of its U.S. business. Investments will include relocation and integration of its commercial and R&D capabilities into a campus in New Jersey and significantly expanded plans for its largest over-the-counter (OTC) manufacturing facility in North Carolina. Reckitt announced up to a $600 million, multi-year transformation of its U.S. operations across two sites to accelerate the long-term growth of its U.S. business. Rendering of Reckitt's New Jersey Research & Development Lab Site, Exterior View Rendering of Reckitt's New Jersey Research & Development Lab Rendering of Reckitt's New Jersey Research & Development Lab Reception Rendering of Reckitt's New Jersey Research & Development Lab Exhibit Alcove Rendering of Rendering of Reckitt's North Carolina Manufacturing Site, External View Speed Speed These phased investments aim to fast-track innovation, sharpen responsiveness to evolving consumer needs, and strengthen supply resilience to ensure reliable access to essential healthcare products. Reckitt employs more than 4,000 employees at seven manufacturing sites and three science and innovation centers across the United States. "With a legacy dating to 1892, Reckitt has maintained a significant presence across the U.S. for more than a century. Our iconic brands including Lysol® and Mucinex® are trusted by millions of American families spanning generations," said Jérôme Lemaire, President, Reckitt North America. "Today's investments will continue building our scientific leadership and R&D, drive new innovations and expand our infrastructure allowing Reckitt to increase access for consumers to high-quality health products." Reckitt recently relocated its North American campus in New Jersey to support commercial and operational teams. As the next phase of development, the company will break ground on a new state-of-the-art science and innovation center with best-in-class capabilities in disinfection, microbiology, surface care, laundry care and personal care. This flagship germ protection hub within Reckitt's global R&D network will be pivotal in advancing Reckitt's portfolio, including Lysol. At the center of this transformation is a new model for innovation that brings together world-class R&D, advanced scientific capabilities, and commercial expertise to speed the path from concept to shelf. "Investing in advanced R&D capability is essential to building for the future," said Angela Naef, Ph.D., Chief R&D Officer, Reckitt. "This investment fundamentally changes how we innovate. By bringing science, insight and execution closer together, we can move faster from discovery to delivery, developing high-quality, science-led solutions that meet evolving consumer needs and scale globally." Reckitt has doubled its initial investment for its state-of-the art OTC manufacturing facility in North Carolina. The site will become its largest OTC manufacturing facility in the U.S. with additional funding supporting expanded production capacity for Mucinex® tablets and liquids, as well as increased production volumes for Move Free®. The site will open in the first half of 2027. This investment also significantly expands the facility's physical footprint, creating the space needed to support future growth, enhance manufacturing flexibility, and accommodate new capabilities as demand evolves. On November 19, the company will be hosting its first Reckitt Focus On event in the United States, where Jérôme Lemaire and other U.S. leaders will showcase the North America business. To register your interest in joining us, please use the following link: event.swisscom.ch/v/northamerica. About Reckitt Reckitt is a world-class consumer health and hygiene company on a mission to deliver better health in more hands, every day. Founded in 1840 in the United Kingdom, Reckitt is home to some of the world's most trusted and recognized brands across Germ Protection, Household Care, Intimate Wellness and Self Care, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet. Operating in more than 80 countries, Reckitt sells approximately 30 million products every day and employs around 36,000 people worldwide. Through trusted brands, science-led innovation and deep consumer understanding, Reckitt helps make health, hygiene and wellbeing more accessible for millions of people while creating sustainable value for consumers, customers, communities and shareholders. For more information, visit reckitt.com/us. Reckitt is the trading name of the Reckitt group of companies Media Contacts Will Hill Global Media Director media&[email protected] Jennifer O'Neill Head of Communications & Corporate Affairs, Americas [email protected] SOURCE Reckitt 21% more press release views with Request a Demo

10 Sep 2026

·www.prnewswire.com

Response Media launches RE:HEALTH to Address Pharma's $300 Billion Adherence Blind Spot¹

New health and life sciences practice debuts AdherenceIQ, an AI-powered platform that predicts patient adherence risk ATLANTA, Sept. 10, 2026 /PRNewswire/ -- Medication nonadherence costs the U.S. healthcare system as much as $300 billion annually. Despite significant investments in awareness, patient acquisition, and new prescription generation, life sciences companies struggle to identify which patients will start/discontinue therapy and understand the emotional barriers driving those decisions. Response Media today announced the launch of RE: HEALTH, a specialized health and life sciences practice built to help pharmaceutical and health brands close that gap. Continue Reading Response Media launches health and life sciences practice to address pharma's $300 billion adherence blind spot Post this RE:HEALTH Logo Backed by decades of healthcare marketing expertise, RE: HEALTH combines behavioral science, privacy-compliant AI and advanced analytics to help brands identify the emotional barriers to treatment and translate that intelligence into engagement strategies that improve adherence, persistence and TRx growth. "Medicine is an emotional decision but the industry has marketed it as a functional one," said Josh Perlstein, Response Media CEO. "We believe there is a smarter approach, and it begins with focusing on the human behind every treatment." With the launch, the company is introducing AdherenceIQ, a proprietary, AI-powered behavioral intelligence platform that predicts and addresses therapy adherence risk before drop-off occurs. Built on published adherence science, AdherenceIQ identifies the emotional and functional barriers preventing patients from starting or continuing therapy, predicts who is most likely to disengage and why, and recommends intervention strategies based on those barriers. For chronic and rare disease therapies, where adherence and persistence are critical to patient outcomes and commercial performance, AdherenceIQ shifts the focus from measuring attrition to identifying patients at risk of disengaging while there is still an opportunity to intervene. "Adherence is too often treated as a reminder problem," said Dr. Alvin Glay, chief strategy officer, RE:HEALTH. "But patients don't make decisions based on reminders. Concerns about side effects, necessity, distrust, and stigma all shape their decisions. We can now uncover those barriers early enough to intervene in a relevant, human way that not only improves patient outcomes but accelerates TRx growth." About Response Media: Ad Age's Data & Insights Small Agency of the Year in 2025, Response Media is a performance marketing agency specializing in data-led CRM/CX strategy and media. The agency has worked with a range of healthcare brands including Bausch + Lomb, Mucinex, Enfamil, and WellStreet Urgent Care. Source1 National Library of Medicine SOURCE Response Media 21% more press release views with Request a Demo

05 Aug 2026

·www.pharmaindustrial-india.com

Reckitt Secures FDA Approval for First OTC Cold and Flu Innovation in 14 Years

Reckitt has announced that the U.S. Food and Drug Administration (FDA) has approved Mucinex 12HR Cold and Fever Multi-Symptom, making it the first Over-the-Counter (OTC) innovation in the cold and flu category to receive FDA approval in 14 years. The approval also marks the first New Drug Application (NDA) approved under the Reckitt name, representing a major regulatory milestone for the consumer health company. The newly approved medicine was developed following more than a decade of scientific research, product development, clinical evaluation and regulatory collaboration. Designed to reflect evolving consumer preferences for convenient, long-lasting symptom management, the product aims to provide extended relief from multiple cold and flu symptoms through a single formulation. The approval comes amid a growing burden of seasonal respiratory illnesses in the United States. According to the U.S. Centres for Disease Control and Prevention (CDC), the 2024–25 influenza season resulted in an estimated 51 million illnesses, while the 2025–26 season experienced an early and widespread surge in flu activity. As consumers increasingly rely on OTC medicines as a first line of self-care, demand for safe, effective and longer-lasting treatment options continues to rise. Mucinex 12HR Cold and Fever Multi-Symptom is the first product in its category to combine guaifenesin, dextromethorphan hydrobromide and naproxen sodium, a Non-Steroidal Anti-Inflammatory Drug (NSAID), in a bilayer tablet. The formulation provides both immediate and extended release of its active ingredients, offering symptom relief that lasts for up to 12 hours—up to three times longer than most conventional cold and flu medicines, according to the company. Reckitt said the product was specifically developed to address the inflammatory processes that contribute to many common cold and flu symptoms, delivering sustained multi-symptom relief in a single dose. With the FDA approval, Reckitt is expanding its portfolio of consumer healthcare products while introducing a new treatment option aimed at improving convenience and symptom management for millions of people affected by seasonal cold and flu illnesses.

Drug Approval

100 Deals associated with Guaifenesin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00337	Guaifenesin	R05CA03	DB00874

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cough	Japan	Kyoto Pharmaceutical Industries Ltd.	20 Mar 1949
Sputum excretion difficulty	Japan	Kyoto Pharmaceutical Industries Ltd.	20 Mar 1949

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute upper respiratory infection	Phase 3	United States	Reckitt Benckiser LLC	01 Sep 2011
Acute upper respiratory tract inflammation	Phase 3	United States	Reckitt Benckiser LLC	01 Sep 2011
Acute respiratory infections	Phase 2	United States	Reckitt Benckiser LLC	01 Apr 2010
Acute lower respiratory tract infection	Phase 2	United States	Reckitt Benckiser, Inc.	01 Dec 2009
Common Cold	Phase 2	United States	Reckitt Benckiser, Inc.	01 Dec 2009
Productive Cough	Phase 1	-	Reckitt Benckiser, Inc.	30 Jun 2009
Respiratory Diseases	Preclinical	United States	Lovelace Respiratory Research Institute	01 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2026	Not Applicable	Idiopathic Pulmonary Fibrosis	46,749	Guaifenesin	awzuvrnlrb(oqqwezvdvp): OR = 1.203 (95.0% CI, 1.051 - 1.377) View more	Positive	15 May 2026
				Benzonatate
NCT06716645 (CTgov)	Phase 4	Cough \| Common Cold	244	Robitussin Maximum Strength Cough+Chest Congestion DM (Robitussin Cough Syrup (Daytime))	xfgtedphcr(whhgffavos) = ihvagjofru eoddcvrhuq (zvxxrdaxhn, kldlhzchkp - ijgidazvtt) View more	-	20 Feb 2026
				Robitussin Maximum Strength Nighttime Cough DM+Chest Congestion DM (Robitussin Cough Syrup (Daytime) + Robitussin Cough Syrup (Nighttime))	xfgtedphcr(whhgffavos) = fdlgaqhwcl eoddcvrhuq (zvxxrdaxhn, azdfijguee - jhewuccdze) View more
NCT01364467 (CTgov)	Phase 2	Chronic rhinitis	30	Placebo (Placebo)	fvccdsbjdp(tuzbbzdsqa) = ppxosprfna lfwpegstze (vxckviyqqi, 0.59) View more	-	24 Apr 2020
				Guaifenesin (Guaifenesin)	fvccdsbjdp(tuzbbzdsqa) = hknnojjvgc lfwpegstze (vxckviyqqi, 1.04) View more
NCT02859246 (CTgov)	Not Applicable	Keratitis	15	Mucinex®	yrsidfcgsi(qbofcxkvdx) = sxdqjfccpn gsryvybssq (idyrhooayz, 2.9) View more	-	19 Feb 2020
NCT03642873 (CTgov)	Phase 1	-	24	Humibid® (Treatment A)	wfmsfqrxtw = mcxlclqqym akspnqocto (qwlizscfgv, gtwnwsawrq - sumtlorkoq) View more	-	20 Jun 2019
				Hydrocodone Bitartrate (Treatment B)	wfmsfqrxtw = hobcjeuakj akspnqocto (qwlizscfgv, ncarrhttrd - qbzjoxrlqg) View more
NCT03644095 (CTgov)	Phase 1	-	30	guaifenesin ER (Test (Treatment A))	liolbwopma(ophwfwwujh) = pahxxrscph elvpocjlel (nuwphpwuwn, 469) View more	-	19 Jun 2019
				Guaifenesin (Reference (Treatment B))	liolbwopma(ophwfwwujh) = xyirxvttar elvpocjlel (nuwphpwuwn, 575) View more
NCT03642262 (CTgov)	Phase 1	-	30	Mucinex® (Treatment A: Mucinex® ER 600 mg)	jrrfyxzzvk(vbogfiozro) = lifeewkcfc iifpujrcbb (srashboyvp, bmitctspgx - fqaudfhlkn) View more	-	17 Jun 2019
				Mucinex® (Treatment B: Guaifenesin 200 mg)	jrrfyxzzvk(vbogfiozro) = zpxqosfpil iifpujrcbb (srashboyvp, mfhqxxgifp - yphwxuuhrk) View more
NCT03633448 (CTgov)	Phase 1	-	24	Guaifenesin (Treatment A (Adolescents))	liabisbisk(jxugipamjt) = jmbnzarlbg ilnagbnmec (swdksqdtmi, 929) View more	-	17 Jun 2019
				Guaifenesin (Treatment A (Adults))	liabisbisk(jxugipamjt) = mtjyjnriau ilnagbnmec (swdksqdtmi, 742) View more
NCT03725085 (CTgov)	Phase 4	Cough \| Pulmonary Congestion	552	Mucinex	nhlaeddjoc = hzmdtwxxln fsobgspaag (prsjukmfzd, xcutzvldxk - vncnqqyiji) View more	-	19 Mar 2019
NCT03633487 (CTgov)	Phase 1	-	24	Mucinex®	hubxnqygvk(duuxclnaqw) = emkmeyzljg nmaxnpnmhl (stanuhfhro, 769.95) View more	-	28 Feb 2019